<DOC>
	<DOCNO>NCT00668499</DOCNO>
	<brief_summary>This single institution non-randomized phase I/II trial patient malignant mesothelioma stage II , receive prior chemotherapy disease . The purpose phase select dose VEGF-AS ( antiangiogenesis drug ) give standard dos pemetrexed follow cisplatin day 1 21-day cycle .</brief_summary>
	<brief_title>A Study VEGF-Antisense Oligonucleotide Combination With Pemetrexed Cisplatin Treatment Advanced Malignant Mesothelioma</brief_title>
	<detailed_description>The Study Objectives Phase I : To determine safety combination VEGF-Antisense Oligonucleotide ( VEGF-AS , Veglin™ ) plus Pemetrexed Cisplatin subject advance Malignant Mesothelioma , .via dose escalation protocol . To determine Maximum Tolerated Dose ( MTD ) Dose Limiting Toxicity ( DLT ) VEGF-AS plus Premetrexed Cisplatin . To determine time disease progression To determine objective response rate combination VEGF-AS plus Pemetrexed Cisplatin treatment advance malignant mesothelioma The study Objectives Phase II : To characterize toxicity experienced patient malignant mesothelioma treat VEGF-AS plus Cisplatin Pemetrexed . To determine median overall survival . The Laboratory objective : To measure plasma VEGF level , , therapy correlate outcome . To determine pharmacokinetic profile VEGF-AS plus Pemetrexed Cisplatin .</detailed_description>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Patients must histologically cytologically confirm malignant pleural mesothelioma , epithelial , sarcomatoid , mixed subtype Patients must measurable disease , use RECIST criteria.Pleural effusion ascites consider measurable lesion . Patients pleural mesothelioma must IMIG stage ≥II Age great equal 18 year . ECOG performance status less equal 2 estimate survival least 3 month Patients must adequate organ marrow function define : Absolute neutrophil count great equal to1,500 Platelets great equal 100,000 Total bilirubin less equal to2.0x upper limit institutional normal AST/ALT le equal 2.0x upper limit institutional normal Creatinine Clearance great 50ml/min The effect VEGFAS develop human fetus unknown . Pemetrexed may cause fetal harm administer pregnant woman classify pregnancy category D. There study pemetrexed pregnant woman . Cisplatin also categorize FDA Pregnancy Category D. There positive evidence human fetal risk . For reason , woman childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ) prior study entry duration study participation . Should woman become pregnant suspect pregnant participating study , inform treat physician immediately . Ability understand willingness sign write informed consent . Patients history prior cure malignancy &gt; 5 year since completion treatment may accrue provided eligibility criterion meet . Patients chemotherapy Mesothelioma prior study entry Patients radiation therapy within 3 week prior enter study . All patient recover toxicity prior therapy . Patients receive therapy investigational agent time study enrollment . Patients uncontrolled brain metastasis Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement Pregnant nursing woman exclude study Patients major surgery within 4 week</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>